LAWRENCE, Mass., March 9, 2017 /PRNewswire/ -- NxStage Medical,
Inc. (NASDAQ: NXTM), a leading medical technology company focused
on advancing renal care, today announced a series of new research
results that highlight the potential for on-site hemodialysis with
the NxStage® System One™ in skilled nursing facilities to
significantly reduce Medicare costs, as well as demonstrate the
clinical benefits of more frequent home hemodialysis. The research
will be presented at the Annual Dialysis Conference
(ADC) 2017 being held March 11-14, 2017,
in California.
On-Site Hemodialysis in Skilled Nursing Facilities:
According to a detailed analysis of data from the United States
Renal Data System, Medicare payments for ambulance service to
transport dialysis patients between skilled nursing and dialysis
facilities totaled over $310 million
annually, or more than 1% of all Medicare spending on dialysis
patients. In fact, the per diem cost of ambulance service
exceeded Medicare's cost or payment for the dialysis treatment
alone.
"At over $310 million in annual
spend, the cost of ambulance services for skilled nursing patients
traveling to and from a dialysis facility is staggering," said
author Dr. Eric Weinhandl, NxStage
clinical epidemiologist and University of
Minnesota-College of Pharmacy adjunct assistant professor.
"Using the System One to provide on-site dialysis to these patients
can directly reduce, and in some cases, eliminate
transportation-related Medicare and Medicaid expenses."
"Considering the high cost burden of these transportation
expenses, the potential cost savings associated with on-site
dialysis with the System One are significant," said Joseph E. Turk, President of NxStage Medical,
Inc. "Existing clinical data shows that when provided on-site, our
therapy can help improve outcomes and quality of life for these
frail patients. With this new data, we can now demonstrate that it
can lower costs in a meaningful way, making it an even better
choice for our health care system."
Dr. Weinhandl will present Medicare Payments for
Transportation between Nursing Institutions and Dialysis
Facilities on March 13th.
More Frequent Home Hemodialysis:
Additional research to be presented at ADC highlights the
clinical benefits of more frequent home hemodialysis with the
System One, including:
- Lower Blood Pressure: On average, patients achieved
pre-dialysis blood pressure significantly lower than in-center
patients.
- Lower Ultrafiltration Rates: Almost all patients
achieved fluid removal rates below National Quality Forum-endorsed
thresholds. Studies have shown ultrafiltration rates below 10
mL/hour/kg are associated with lower risks of death and
hospitalization.
Dr. Weinhandl will present this research within the abstracts
Blood Pressure Control on More Frequent Home Hemodialysis
and Ultrafiltration Rates with More Frequent Home
Hemodialysis on March 13th. Dr.
Weinhandl's poster, Post-Dialysis Recovery Time in the
Frequent Hemodialysis Network, will be available for viewing on
March 12th and 13th.
Dr. Maxence Ficheux of CHU
Hospital Clemenceau, will present data showing that the NxStage
System One can be used to achieve effective clearance of small
molecules and lower the use of blood pressure medications in
patients across a broad range of body mass index (BMI) categories,
including those with a normal BMI as well as obese patients. The
abstract, European Experience with NxStage System One for Home
Hemodialysis across Diverse Body Mass Indices, will be
presented on March 13th.
About the NxStage System One
The NxStage System One is the first and only truly portable
hemodialysis system cleared specifically by the FDA for home
hemodialysis and home nocturnal hemodialysis. Its simplicity and
revolutionary size (just over a foot tall) are intended to allow
convenient use in patients' homes and give patients the freedom to
travel with their therapy. When combined with the NxStage PureFlow™
SL Dialysis Preparation System, patients are able to further
simplify, using ordinary tap water to create dialysis fluid on-site
on-demand. Unlike conventional hemodialysis systems, the System One
requires no special infrastructure to operate. Under the guidance
of their physician, patients can use the NxStage System One, with
their trained partners, where, how and when it best meets their
needs, including while they are sleeping - at home or on vacation
and at a medically appropriate treatment frequency. In addition,
NxStage's Nx2me Connected Health® platform collects important
NxStage System One and patient information for flexible viewing,
monitoring and reporting that may improve patient management and
patient retention, as well as simplify alternative site care. The
System One is also used to provide a range of flexible therapy
options in more traditional care settings such as hospitals and
dialysis centers. Its safety and performance have been demonstrated
by experience with more than 14 million treatments with over 30
thousand patients around the world.
https://protect-us.mimecast.com/s/vlZoBxc3XJr7UZ?domain=nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. NxStage
also has established a small number of dialysis clinics committed
to the development of innovative care delivery models for patients
with ESRD. For more information on NxStage and its products and
services, please visit the Company's websites at
https://protect-us.mimecast.com/s/VAGKB8sKdv0lTa?domain=nxstage.com and https://protect-us.mimecast.com/s/g50DBnu38NL7Ur?domain=nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended
December 31, 2016. NxStage is under
no obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact:
Kristen K.
Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-data-shows-significant-potential-cost-savings-with-on-site-hemodialysis-in-skilled-nursing-facilities-300420684.html
SOURCE NxStage Medical, Inc.